keyword
MENU ▼
Read by QxMD icon Read
search

Cardioncology

keyword
https://www.readbyqxmd.com/read/27755239/pathophysiology-of-cardiotoxicity-from-target-therapy-and-angiogenesis-inhibitors
#1
Nicola Maurea, Carmela Coppola, Giovanna Piscopo, Francesca Galletta, Gennaro Riccio, Emanuela Esposito, Claudia De Lorenzo, Michelino De Laurentiis, Paolo Spallarossa, Giuseppe Mercuro
The progress in cancer therapy and the increase in number of long-term survivors reveal the issue of cardiovascular side-effects of anticancer drugs. Cardiotoxicity has become a significant problem, and the risks of adverse cardiac events induced by systemic drugs need to be seriously considered. Potential cardiovascular toxicities linked to anticancer agents include arrhythmias, myocardial ischemia and infarction, hypertension, thromboembolism, left ventricular dysfunction, and heart failure. It has been shown that several anticancer drugs seriously affect the cardiovascular system, such as ErbB2 inhibitors, vascular endothelial growth factor (VEGF) inhibitors, multitargeted kinase inhibitors, Abelson murine leukemia viral oncogene homolog inhibitors, and others...
May 2016: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/27183521/pathophysiology-of-cardiotoxicity-from-target-therapy-and-angiogenesis-inhibitors
#2
Nicola Maurea, Carmela Coppola, Giovanna Piscopo, Francesca Galletta, Gennaro Riccio, Emanuela Esposito, Claudia De Lorenzo, Michelino De Laurentiis, Paolo Spallarossa, Giuseppe Mercuro
The progress in cancer therapy and the increase in number of long-term survivors reveal the issue of cardiovascular side-effects of anticancer drugs. Cardiotoxicity has become a significant problem, and the risks of adverse cardiac events induced by systemic drugs need to be seriously considered. Potential cardiovascular toxicities linked to anticancer agents include arrhythmias, myocardial ischemia and infarction, hypertension, thromboembolism, left ventricular dysfunction, and heart failure. It has been shown that several anticancer drugs seriously affect the cardiovascular system, such as ErbB2 inhibitors, vascular endothelial growth factor (VEGF) inhibitors, multitargeted kinase inhibitors, Abelson murine leukemia viral oncogene homolog inhibitors, and others...
May 2016: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/27108361/curing-cancer-saving-the-heart-a-challenge-that-cardioncology-should-not-miss
#3
REVIEW
Daniela Cardinale, Gina Biasillo, Carlo Maria Cipolla
Advances in oncologic therapies have led to considerable improvements in prognosis and survival. However, these improvements may ultimately be diminished by the increase of cardiovascular side effects. Typically, both conventional and new antitumoral therapies may induce asymptomatic or symptomatic left ventricular dysfunction. Its development still remains a major deterrent that may compromise clinical effectiveness of cancer treatment, independently of the oncologic prognosis, having a serious impact on the patient's survival and quality of life...
June 2016: Current Cardiology Reports
https://www.readbyqxmd.com/read/27038642/cardio-oncology-training-a-proposal-from-the-international-cardioncology-society-and-canadian-cardiac-oncology-network-for-a-new-multidisciplinary-specialty
#4
Daniel J Lenihan, Gregory Hartlage, Jeanne DeCara, Anne Blaes, J Emanuel Finet, Alexander R Lyon, Robert F Cornell, Javid Moslehi, Guilherme H Oliveira, Gillian Murtagh, Michael Fisch, Gary Zeevi, Zaza Iakobishvili, Ron Witteles, Aarti Patel, Eric Harrison, Michael Fradley, Giuseppe Curigliano, Carrie Geisberg Lenneman, Andreia Magalhaes, Ron Krone, Charles Porter, Susmita Parasher, Susan Dent, Pamela Douglas, Joseph Carver
There is an increasing awareness and clinical interest in cardiac safety during cancer therapy as well as in optimally addressing cardiac issues in cancer survivors. Although there is an emerging expertise in this area, known as cardio-oncology, there is a lack of organization in the essential components of contemporary training. This proposal, an international consensus statement organized by the International Cardioncology Society and the Canadian Cardiac Oncology Network, attempts to marshal the important ongoing efforts for training the next generation of cardio-oncologists...
June 2016: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/26526839/the-role-of-the-metabolism-of-anticancer-drugs-in-their-induced-cardiotoxicity
#5
Ana Filipa Reis-Mendes, Emília Sousa, Maria de Lourdes Bastos, Vera Marisa Costa
Cardioncology is a major topic of the day, since cardiotoxicity of chemotherapy agents can limit its real use and it can also become a clinical problem years after the end of anticancer therapy. These cardiac problems largely increase the mortality and morbidity of cancer-treated patients. Actually, as the number of cancer survivors is increasing each decade, late cardiotoxicity related to anticancer therapy is expected to grow exponentially in the fore coming years. The mechanisms of cardiotoxicity of anticancer drugs are still largely unknown...
2015: Current Drug Metabolism
https://www.readbyqxmd.com/read/26198827/cardio-oncology-a-tremendous-opportunity-to-improve-patient-care
#6
Daniel J Lenihan, Gemma Westcott
A cardiologist at Vanderbilt University (TN, USA), Daniel J Lenihan is President of the International CardiOncology Society-North America. In 1988, Daniel graduated from the University of Tennessee College of Medicine at Memphis and did his residency at Wright-Patterson Air Force Base in Dayton (OH, USA). Ultimately, he gained a cardiology fellowship from the University of Cincinnati (OH, USA) and went on to become Professor and Director of Cardiovascular Research in the Department of Cardiology at The University of Texas MD Anderson Cancer (TX, USA)...
2015: Future Oncology
https://www.readbyqxmd.com/read/26059938/prevention-and-treatment-of-cardiac-dysfunction-in-breast-cancer-survivors
#7
Carol Fabian
As recurrence free survival following a breast cancer diagnosis continues to improve, cardiovascular morbidity and mortality will assume greater importance in the breast cancer survivorship research agenda particularly for women receiving potentially cardiotoxic therapy. Development of (1) tools to readily identify pre-diagnostic risk factors for cardiac dysfunction, (2) well-tolerated prophylactic treatments to reduce the risk of cardiac injury, and (3) sensitive and affordable monitoring techniques which can identify subclinical toxicity prior to a drop in left ventricular ejection fraction are or should be focus areas of cardio-oncology research...
2015: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/25671635/effects-of-5-fluorouracil-on-morphology-cell-cycle-proliferation-apoptosis-autophagy-and-ros-production-in-endothelial-cells-and-cardiomyocytes
#8
Chiara Focaccetti, Antonino Bruno, Elena Magnani, Desirée Bartolini, Elisa Principi, Katiuscia Dallaglio, Eraldo O Bucci, Giovanna Finzi, Fausto Sessa, Douglas M Noonan, Adriana Albini
Antimetabolites are a class of effective anticancer drugs interfering in essential biochemical processes. 5-Fluorouracil (5-FU) and its prodrug Capecitabine are widely used in the treatment of several solid tumors (gastro-intestinal, gynecological, head and neck, breast carcinomas). Therapy with fluoropyrimidines is associated with a wide range of adverse effects, including diarrhea, dehydration, abdominal pain, nausea, stomatitis, and hand-foot syndrome. Among the 5-FU side effects, increasing attention is given to cardiovascular toxicities induced at different levels and intensities...
2015: PloS One
https://www.readbyqxmd.com/read/23669115/cardioncology-oncocardiology-are-we-barking-up-the-wrong-tree
#9
EDITORIAL
C Lestuzzi
No abstract text is available yet for this article.
July 31, 2013: International Journal of Cardiology
https://www.readbyqxmd.com/read/23651420/cardiovascular-safety-and-hemodynamic-considerations-in-oncology-drug-development-webinar-highlights-october-10th-2012
#10
REVIEW
Martin Braddock, Jeff Heilbraun, Boaz Mendzelevski
INTRODUCTION: Development of new drugs in oncology may have implications for cardiovascular risk. This report describes some aspects of our growing knowledge in the area of evaluating benefit-risk and may be of direct importance to scientists working in drug discovery and development. AREAS COVERED: This report of webinar highlights entitled "Trends in CardiOncology: the evolution of blood pressure and electrocardiogram (ECG) Markers" covers the current state of pharmacology of selected drugs which induce blood pressure elevation and best practices in employing the measurement of blood pressure elevation and cardiac safety parameters for drug development in oncology...
September 2013: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/23639459/cardioncology-state-of-the-heart
#11
REVIEW
Maria Chiara Todaro, Lilia Oreto, Rubina Qamar, Timothy E Paterick, Scipione Carerj, Bijoy K Khandheria
Cardiotoxicity caused by chemotherapy is a concerning reality plaguing oncologists and cardiologists. The coexistence of cancer and cardiovascular diseases in the same patient is more common due to the aging population and improvement of chemotherapeutic drug effectiveness. We review the incidence and clinical features of cardiotoxicity caused by some of the most common chemotherapeutic drugs to provide the cardiologist with information regarding general cardiovascular toxicity, early left ventricular dysfunction detection, cardiac damage prevention and follow-up...
September 30, 2013: International Journal of Cardiology
https://www.readbyqxmd.com/read/22351966/heart-disease-and-cancer-the-new-discipline-of-cardioncology
#12
Jennifer Taylor
No abstract text is available yet for this article.
January 2012: European Heart Journal
https://www.readbyqxmd.com/read/21892906/role-of-biomarkers-in-cardioncology
#13
REVIEW
Daniela Cardinale, Michela Salvatici, Maria T Sandri
Cardiotoxicity is a serious adverse effect of anticancer drugs, impacting on quality of life and overall survival of cancer patients. According to the current standard for monitoring cardiac function, cardiotoxicity is usually detected only when a functional impairment has already occurred, precluding any chance of preventing its development. Over the last decade, however, a new approach, based on the use of cardiac biomarkers, has emerged, and has proven to be an effective alternative strategy for early detection of subclinical cardiac injury...
December 2011: Clinical Chemistry and Laboratory Medicine: CCLM
https://www.readbyqxmd.com/read/21509755/cardioncology-pioneer-sees-promise-in-new-drugs-case-management-approaches
#14
Carrie Printz
No abstract text is available yet for this article.
May 1, 2011: Cancer
https://www.readbyqxmd.com/read/21509753/international-cardioncology-society-tackles-heart-problems-in-cancer-patients-collaboration-between-2-specialties-focuses-on-mutual-challenges-for-patients
#15
https://www.readbyqxmd.com/read/20728695/the-compelling-need-for-a-cardiology-and-oncology-partnership-and-the-birth-of-the-international-cardioncology-society
#16
Daniel J Lenihan, Daniela Cardinale, Carlo M Cipolla
Cardiac disease in patients with cancer is common and influences the longevity and quality of life both of patients in active treatment and of survivors of cancer. The disciplines of cardiology and oncology have increasingly recognized the benefits to patients of collaborating in the care of cancer patients with cardiac disease. This increased recognition arises from several factors: the aging population in which both cardiac and cancer diagnoses are common; the cellular and molecular therapeutic targets of newer medical treatments, and, in particular, the specific patient treatment choices and decisions that require careful, effective clinical interactions between these 2 disciplines...
September 2010: Progress in Cardiovascular Diseases
https://www.readbyqxmd.com/read/20036530/from-cancer-patients-to-cancer-survivors-the-issue-of-cardioncology-a-biological-perspective
#17
REVIEW
Alberto Zambelli, Matteo Della Porta, Vittorio Rosti
Long-term survival of cancer patients can be worsened by cardiovascular morbidity and mortality due to anticancer treatments based on cardiotoxic or antiangiogenic regimens. Growing scientific evidences support a role for circulating endothelial progenitor cells (EPCs) both in cancer pathogenesis and in cardiovascular diseases. High frequency of circulating EPCs seems to play a role in cancer growth and dissemination by favouring tumor angiogenesis and estabilishment of sites of metastasis. On the other hand, high level of circulating EPCs seems to be associated with a lower risk of developing cardiovascular diseases and with improved vascular regeneration after cardiovascular damage...
March 2010: European Journal of Cancer
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"